Inflammation Remains Treatment Target Despite ZEUS Trial Results

The phase III ZEUS clinical trial found that the medication ziltivekimab did not significantly reduce cardiovascular risks in patients with chronic kidney disease and atherosclerosis. Despite these results, researchers maintain that targeting inflammation remains a critical area for future cardiovascular treatment.
Why it matters
The failure of this trial highlights the ongoing difficulty in treating high-risk cardiovascular patients and underscores the complexity of inflammation-based therapies.
This news release includes additional data and findings from the research author.
CHICAGO, Nov. 7, 2026 - A novel medication called ziltivekimab that lowered markers of inflammation in the blood did not significantly reduce the combined risk of heart attack, stroke or cardiovascular death in very high risk adults with atherosclerotic cardiovascular disease (ASCVD) and chronic kidney disease, according to the phase III clinical trial called ZEUS. The detailed findings of ZEUS were shared in a late-breaking science session presented today at the American Heart Association's Scientific Sessions 2026 . The meeting, Nov. 6-9 in Chicago, is a premier global exchange of the latest scientific advancements, research and evidence-based clinical practice updates in cardiovascular science.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in